Sort   by:  
 Page size 
UnknownA phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy.
Not available
S-EPMC5664308 | biostudies-literature
UnknownImpact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
Not available
S-EPMC7618536 | biostudies-literature
UnknownEffects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
Not available
S-EPMC7615591 | biostudies-literature
UnknownMelanoma-Secreted Amyloid Beta Suppresses Neuroinflammation and Promotes Brain Metastasis.
Not available
S-EPMC9069488 | biostudies-literature
UnknownAlzheimer disease brain atrophy subtypes are associated with cognition and rate of decline.
Not available
S-EPMC5696639 | biostudies-literature
UnknownFrailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.
Not available
S-EPMC11390031 | biostudies-literature
UnknownLong-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
Not available
S-EPMC7616743 | biostudies-literature
UnknownEffects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.
Not available
S-EPMC12274867 | biostudies-literature
UnknownEmpagliflozin in Patients with Chronic Kidney Disease.
Not available
S-EPMC7614055 | biostudies-literature
UnknownClinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration.
Not available
S-EPMC6988137 | biostudies-literature
Sort   by:  
 Page size